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Abstract 
Retinoids have a wide variety of applications.  They can act as potent inducers of stem 
cell differentiation,  as chemopreventative and chemotherapeutic agents,  and have 
been utilised for the treatment of dermatological conditions.  However,  natural 
retinoids readily undergo photo-isomerisation in the presence of natural light and / or in 
physiological conditions.  This propensity for isomerisation is believed to be the cause 
of many unwanted problems / side effects.  Synthetic retinoids have been made by 
replacing key functional groups with more robust pharmacophores which retain the key 
functionalities of natural retinoids but are resistant to isomerisation.  Previous studies 
have shown that synthetic retinoids,  such as EC23 and EC19 have very high stability 
and are more potent than their natural analogues ATRA and 13cisRA.   
The high potency of synthetic retinoids such as EC23 implies that they do not undergo 
metabolism.  An in vivo investigation into the metabolism of retinoids was initiated.  
AG1-X2 polymer beads were used to deliver various concentrations of AT-retinol 
solutions in DMSO to the anterior margin of a stage 20 chick limb bud which was then 
observed at stage 36 for signs of abnormal development such as digit duplication.  
Occurrence of digit duplication would suggest that AT-retinol had been metabolised to 
ATRA,  a known inducer of teratogenic effects,  within the limb bud;  however,  only 
normal development was observed.  This suggests that an alternative route for 
delivering uncharged molecules to limb buds is required. 
Sonogashira cross coupling reactions were employed to synthesise ether acetate 
analogues of EC23 and EC19,  (EC23-OAc and EC19-OAc) from TMNA with acetic 
acid 4-bromo-benzyl ester and acetic acid 3-iodo-benzyl ester respectively,  with the 
intention of hydrolysing them into EC23-OH and EC19-OH,  i.e.  synthetic analogues 
of AT-retinol,  to be investigated for teratogenic effects in the chick limb-bud as above.  
If successful delivery of AT-retinol produced limb defects,  while EC23-OH did not,  
this would be consistent with the idea that EC23 and its analogues are refractory to 
normal retinoid metabolism. 
A variety of useful retinoid precursors were also synthesised from cross coupling 
reactions and borylation techniques.  Synthetic retinoids methyl 5',6',7',8'-tetrahydro-
2,2'-binaphthyl-6-carboxylate and (E)-methyl-3-(4-(5,6,7,8-tetrahydronaphthalen-2-
yl)phenyl)acrylate were made by Suzuki-Miyaura Cross-coupling reactions,  also to be 
tested in vivo. 
1 
  
Acknowledgements 
 
I‟d like to give a huge thank you to my supervisor Todd for his endless patience,  
encouragement enthusiasm.  I would also like to give a big thanks to Paul,  who 
has also spent a great deal of time,  explaining and teaching me biological 
techniques.  Andy too has shown much support and given many great 
suggestions,  for which I‟m very grateful.  
 
I would not have made it this far if it had not been for the warmth and friendliness 
of the rest of the group.  I‟m grateful for Jon and Jonathan who were always on 
hand to teach me techniques and help me out and for Meng Guan and Manolo 
for their reassurance.  Thank you to Pete and Andrew for their continued help 
and patience – especially with my seemingly never ending columns – and for 
making me laugh.  Thanks also to Andreas for the hours spent helping me with 
written work.  I am incredibly thankful for the support of Emma and Marie Hélène 
for making me tea when it was all too much and not letting me drop that potato!  
Bianca – It‟s difficult to feel anything but positive when you‟re around!   Thanks 
also to Christian, Nim, Liu Chao and Hazmi for great ideas, fantastic cakes and 
lots of laughs.  I‟ve never known such a lovely group.  I‟ve really enjoyed getting 
to know you and will miss you all.  Thank You! 
 
1 
  
Contents 
Abstract ......................................................................................................... 2 
Chapter 1:   Introduction ............................................................................... 4 
1.1 Natural Retinoids .......................................................................................4 
1.2 Applications ................................................................................................6 
  Applications:   Cancer Therapy (Leukaemia)...................................... 7 
  Applications:   Skin Treatment ............................................................ 8 
  Applications:   Stem Cell Differentiation ............................................ 11 
1.3 Developing Synthetic Derivatives of Natural  Retinoids ..........................13 
1.4 Chick Limb Development .........................................................................17 
  The Morphogen Gradient Model ....................................................... 18 
  Investigation into Metabolism of Retinoids ....................................... 22 
1.5 Synthetic Strategy: Pd-Catalysed Cross-Coupling  Reactions ...............23 
  Oxidative Addition.............................................................................. 25 
  Transmetallation ................................................................................ 25 
  Reductive Elimination ........................................................................ 26 
  The Sonogashira Reaction ................................................................ 26 
Chapter 2:   Chemical Synthesis, Results and Discussion ...................... 29 
2.1 Synthesis of Starting Materials ................................................................29 
2.2 Retinoids from Suzuki-Miyaura Cross-coupling ......................................34 
2.3 Route to Benzyl Alcohol ...........................................................................37 
Chapter 3:   Biological Results and Discussion ........................................ 41 
3.1 Serial Dilution of Retinoid Solutions ........................................................41 
3.2 Development of Procedures for In Vivo Analysis of  Retinoid Action .....42 
3.3 Loading and Unloading Assays ...............................................................45 
3.4 Effect of EC23 on Chick Limb Development ...........................................48 
3.5 Effect of Retinol on chick limb development ...........................................50 
3.6 Proposed Explanation of Findings ...........................................................51 
3.7 Conclusions..............................................................................................51 
3.8 Future Work .............................................................................................52 
Chapter 4:   Experimental ........................................................................... 57 
6.1 Chemical Synthesis .................................................................................58 
6.2  Biological Procedures ..............................................................................65 
References ................................................................................................... 69 
 
2 
  
Abbreviations 
 
9cisRA  9-cis retinoic acid 
13cisRA  13-cis retinoic acid; Isotretinoin 
A   Absorbance 
A.C.S.   A.C.S. grade reagent meets the specifications of the   
   American Chemical Society 
AER   Apical ectodermal ridge  
APL   Acute promyelocytic leukaemia  
ASAP   Atmospheric pressure solids analysis probe 
AT   All-trans  
ATRA   All-trans retinoic acid; Tretinoin 
CNS   Central nervous system 
CRABP   Cellular retinoic acid binding protein 
CRBPs   Cellular retinol binding protein 
DCM   Dichloromethane 
dppf   1,1'-bis(diphenylphosphino)ferrocene 
dtbpy   4,4´-di-tert-butyl-2,2´-bipyridine 
ESI   Electro spray ionisation 
EC   Embryonal carcinoma 
GC-MS  Gas chromatography – Mass spectrometry 
HRMS   High Resolution Mass Spectrometry 
IPS cells  Inducible pluripotent stem cells 
LBP   Ligand binding pocket 
LRAT    Lecithin retinol-acyl-transferase 
neop   Neopentylglycolato 
NMR   Nuclear magnetic resonance 
pin   Pinacolato (OCMe2CMe2O) 
ppm   Parts per million 
QTOF   Quadrupole time of flight 
3 
  
RA   Retinoic acid 
RAR-α,β,γ  Retinoic acid receptors; α, β and γ isotypes 
RXR-α,β,γ  Retinoid X receptors; α, β and γ isotypes 
Shh   Sonic hedgehog gene 
S-phos  2-Dicyclohexylphosphino-2‟,6‟-dimethoxybiphenyl 
TMNA   6-Ethynyl-1,1,4,4-tetramethyl-1,2,3,4-    
   tetrahydronaphthalene 
tlc   Thin layer chromatography 
ZPA   Zone of polarising activity 
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Chapter 1:   Introduction 
 
1.1 Natural Retinoids 
The retinoids are a group of natural and synthetic molecules which have a 
structure and / or function related to vitamin A.  Natural retinoids are important for 
embryonic development and play key roles in the development of organs and 
systems such as the heart1 and central nervous system.2  They also play crucial 
roles in the adult organism,  regulating important biological processes including 
vision,3  immune defence,3  sleep regulation4  and cellular regulation and 
differentiation.2   Disregulation of the retinoid pathway is associated with 
neurological disorders such as Schizophrenia,  Alzheimer‟s and motor neurone 
disease.2  
 
Close regulation of vitamin A levels is crucial in maintaining bodily processes.  
Vitamin A cannot be synthesised by mammals and must be ingested either in the 
form of provitamin A from plants or preformed vitamin A from animal products.  In 
humans, the major storage site is the liver,  where it is stored in the form of retinyl 
palmitate.  It is then transported in the form of retinol bound to retinol binding 
protein to tissues in the body as required.  Diets either too high or too low in 
vitamin A can result in severe disorders and extreme deviations from optimum 
levels may be fatal.5  
 
Vitamin A deficiency is characterised by xerophthalmia (dry eyes), night 
blindness and impaired immune responses which can be fatal.2  At the other 
extreme,  excessive intake of vitamin A,  known as hypervitaminosis A,  can 
result in problems with the skin,  nervous system,  circulation,  bone formation 
and immune system.2  Hypervitaminosis A is also associated with osteoporosis.6  
Abnormal vitamin A levels can cause teratogenic effects,  as evidenced by the 
occurrence of birth defects in the offspring of mothers with either excessive or 
5 
  
restricted intakes during early pregnancy.7  Regulation of vitamin A levels is 
therefore crucial both for normal development and regulation of biological 
processes. 
 
 
 
Figure 1:  Common isomeric forms of retinoic acid.  
 
 
Retinoic acid (RA),  a well studied metabolite of vitamin A,  exists in several 
isomeric forms including all-trans-retinoic acid (ATRA),  13-cis-retinoic acid 
(13cisRA) and 9-cis-retinoic acid (9cisRA), as shown in Figure 1.  Interconversion 
between the different isomers is facile,  especially in the presence of light.  ATRA 
is the most thermodynamically stable and is the major isomer at equilibrium.  It is 
converted in the body from ingested retinol, via a two step reaction,8  shown in 
Scheme 1.  Retinol is reversibly converted to retinal by retinol dehydrogenase,  
which is then irreversibly converted to ATRA by retinal dehydrogenase.9  Retinoid 
activity arises mainly from the activation of three retinoic acid receptors (RAR α, 
β and γ) and three retinoic X receptors (RXR α, β and γ).10  The receptors have 
varying affinity for the different isomers. 
 
 
COOH
COOH
COOH
All-trans-retinoic acid 13-cis-retinoic acid 9-cis-retinoic acid
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Scheme 1:  Enzymatic conversion of ATRA to AT-retinol. 
 
 
1.2 Applications 
 
The high biological activity of retinoids lends them to a wide variety of medical 
applications.  For example,  retinoid-based therapies show promise in the 
treatment of eye diseases such retinal dystrophies11  and macular 
degeneration.12  An early use of ATRA was in the treatment of skin conditions 
such as acne13, 23 and psoriasis.26  Use of retinoids such as ATRA and 13cisRA 
have considerably improved the management and prognosis of certain cancers 
including prostate14,15,16 and breast cancers,17  leukaemia,19, 21,20 and 
neuroblastoma.18  The ability of retinoids to induce differentiation of stem cells 
has been utilized to grow tissues in vitro.34 
OH
O
All-trans-retinoic acid
H
O
All-trans-retinal
OH
retinol dehydrogenase
retinal dehydrogenase
All-trans-retinol
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Applications:   Cancer Therapy (Leukaemia) 
Retinoids are able to control differentiation and apoptosis of tumour cells,  giving 
them therapeutic potential for cancer treatment and prevention.  The introduction 
of ATRA into the therapy of acute promyelocytic leukaemia (APL) has completely 
revolutionised its management and outcome.  A characteristic of this disease is 
that the cells are blocked at an early stage of their development and are unable 
to differentiate into functional mature cells.19  Whilst traditional cytotoxic therapies 
simply kill cancer cells,  ATRA can reverse malignant cell growth.20  The new 
treatment theoretically avoids the undesirable side effects of cytotoxic therapies 
and has drastically improved remission and cure rates.19  
 
The major difficulty with ATRA therapy is the rapid resistance patients develop to 
the treatment.9,19,20  Both in vivo and in vitro studies have shown RA metabolism 
increases with increasing ATRA therapy.20  It is therefore suggested that 
metabolism plays a key role in ATRA resistance.9  Improvements in drug delivery 
methods such as encapsulation in liposomes have been shown to slow ATRA 
metabolism;20  however,  currently the most effective way to combat ATRA 
resistance is combined therapy with arsenic trioxide (ATO).19,21  
 
The side effects of ATRA therapy,  whilst  much milder than those caused by 
traditional cytotoxic therapies,  are still unpleasant and undesirable.   They 
include hepatoxicity (chemical-driven liver damage),  headaches,  nausea,  
vomiting,  abdominal pain and mucocutaneous dryness (dryness of skin found at 
the orifices)20 and are attributed to isomers of ATRA,  such as 13cisRA,  which 
are formed readily under physiological conditions.  The development of synthetic 
retinoids which have the same key functionalities as ATRA and 13cisRA,  yet are 
resistant to metabolism and isomerisation,  may be a new approach to 
overcoming the resistance and side effects of current retinoid treatment.  
8 
  
 
Applications:   Skin Treatment 
Retinoids are used widely and successfully in the treatment of skin conditions 
such as acne and psoriasis.  The effects of topical ATRA (also known as 
tretinoin) was first reported by Stuttgen and Beer in 1962.22  Since then,  three 
generations of topical retinoids have been developed.  Today,  the major 
commercially available retinoids are tretinoin,  tazarotene and adapalene (Figure 
2). 
 
Figure 2: Major commercially available retinoids:  First generation retinoid 
tretinoin, along with third generation retinoids adapalene and tazarotene. 
 
In 1972,  ATRA became the first topical retinoid used for the treatment of acne.23  
Derivatives of ATRA,  namely retinol and 13cisRA (also known as isotretinoin) 
were also amongst the early topical retinoids.  It is believed that 13cisRA is 
isomerised to ATRA24 which then interacts with RAR receptors to regulate 
pathogenic factors associated with acne,  specifically,  normalising keratinisation 
MeO
O
S
N
O
O
Adapalene Tazarotene
OH
O
Tretinoin (ATRA)
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of the follicular infundibulumi,  normalising propionibacterium acnesii mediated 
responses and reducing inflammation.23  Early preparations caused severe skin 
irritation such as redness,  scaling,  itching,  burning,  blistering and thinning of 
the skin.  ATRA is currently the only topical retinoid available in generic 
formulations and is therefore significantly cheaper than others.23  For this reason,  
despite its unpleasant side effects and the fact that it is a reported human 
teratogen,25 ATRA is still used widely as a skin treatment. 
 
Acitretin (shown in Figure 3) is a synthetic systemic retinoid taken orally for the 
treatment of severe psoriasis.26  It is a non selective activator of retinoic acid 
receptors RAR α, β and γ26  and acts to reduce the severity of scaling,  erythema 
(redness of the skin) and induration27 (hardening of the skin).  The side effects 
associated with oral retinoids are more severe than those of their topical 
counterparts and include elevation of liver enzymes,  hyperostosis28 (excessive 
bone growth) and elevation of cholesterol;27 therefore,  acitretin is only prescribed 
to patients who have not responded to topical retinoid treatment.  Acitretin can 
cause teratogenic effects up to three years after discontinuation and has 
accordingly been assigned as a pregnancy category X.29  
 
Etretinate (shown in Figure 3),  the ethyl ester form of acitretin,  was also 
administered to treat psoriasis until it was discovered it had an elimination half-
life of 80-175 days.30  Its long elimination half life is attributed to it being highly 
lipophilic and therefore it readily accumulates in skin tissue.  As a build up of 
teratogenic drugs is highly undesirable,  etretinate was withdrawn in favour of the 
acid derivative,  acitretin,  which has an elimination half life of only 2-3 days.  
However,  it was later discovered that in the presence of ethanol,  acitretin can 
be esterified to etretinate.31  It is therefore important that patients taking acitretin 
do not consume alcohol.  This should also serve as a warning as to the extreme 
                                                 
i
 I.e. regulation of the formation of skin around the hair follicles.  In acne patients, improper 
regulation of this process leads to a build up of dead skin cells which block the pores.  
ii
 A bacteria with the potential to break down the walls of pores in the skin. 
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care and attention required when taking,  administering and working with 
retinoids.  Whilst the exact metabolic pathways are unknown it should be 
presumed that all forms of retinoids have the potential to be converted into active 
and / or long lived forms.  All retinoids, especially synthetic ones, should be 
treated as highly teratogenic. 
 
 
Figure 3:  Second generation retinoids, Acitretin and Etretinate. 
Third generation synthetic retinoids have been developed to show greater 
receptor specificity and lesser side effects than their first and second generation 
counterparts.  Adapalene (shown in Figure 2) was the first synthetic retinoid used 
in the topical treatment of acne.  Like ATRA,  it regulates keratinisation and has 
anti-inflammatory properties;  however, unlike ATRA it is selective for RAR β/γ 
and does not bind to CRABPs (cellular retinoic acid binding proteins).  
Tazarotene, (shown in Figure 2) also used in the treatment of acne and psoriasis,  
is rapidly converted into tazarotenic acid, its active metabolite.  The primary 
effects of Tazarotene are regulation of cell differentiation and down-regulation of 
proinflammatory mediators.23  Tazarotene is able to bind all three RARα/β/γ but 
shows increased affinity to RARβ and γ.  Both Adapalene and Tazarotene have 
less unwanted side reactions than the RAR pan agonist ATRA and this is 
attributed to their greater selectivity. 
 
Difficulties with the use of Retinoids in Skin Treatment 
Retinoid therapies have shown excellent results in the treatment of skin 
OH
O
O
O
O
O
EtretinateAcitretin
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conditions;  however, t hey should be administered with caution due to their 
potential teratogenic effects.  The teratogenic risks posed by oral retinoids is 
much greater than those for topical retinoids.  All retinoid treatment is 
contraindicated for use in the early stages of pregnancy,  and it is recommended 
that oral treatment must be ceased at least three years prior to conception.26 
 
The facility of natural retinoids to isomerise can cause further problems with their 
use as skin treatment agents.  Under physiological conditions,  their conversion 
into other isomersiii may induce additional biological pathways,  resulting in 
unwanted side effects.  Synthetic third generation retinoids generally have milder 
side effects than natural first generation retinoids and this may be attributed to 
their enhanced receptor specificity along with their increased resistance to 
isomerisation.  The ability of natural retinoids to isomerise readily in natural light 
results in degradation of the active ingredient in the formulation,  and therefore 
leads to reduced potency.  An interesting approach to this problem is a 
recommendation to “use at night” on patient leaflet!32   A more practical solution 
is the microencapsulation of ATRA,  which has been shown to dramatically 
reduce photodegredation and also reduce skin irritation.32  A photostable 
synthetic derivative of ATRA,  discussed later, has been developed.  This could 
be a future,  more stable,  alternative to the use of natural retinoids.   
 
Applications:   Stem Cell Differentiation 
Retinoids are also utilised to grow tissues in vitro.  Generally embryonal 
carcinoma (EC) cells,  the stem cells of tetracarcinomers,  differentiate to form a 
wide variety of cell types;  however, certain EC cell lines do not have the capacity 
to differentiate and are propagated primarily as stem cells.  It is possible to 
                                                 
iii
 Although it is important to note that isomerisation could be important in their mode of 
action
20 
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induce differentiation in these cell lines with small molecules,  such as ATRA.49  
For example TERA.cl.SP12 cells are known for their ability to form neurons in 
response to ATRA,33 34  thus facilitating the production of neural tissues which 
can potentially be used for drug screening,  toxicological testing,  research into 
neuron disorders and the development of therapies. 
 
Once again,  the propensity for ATRA to isomerise is undesirable.  Murayama et 
al., issued a warning in 1997,  stating that when exposed to fluorescent lamps,  a 
solution of ATRA undergoes significant isomerisation within 30 minutes. 35  The 
outcome of cell differentiation is often dependent on both the concentration and 
identity of isomer(s) present,  thus uncontrolled isomerisation leads to variation in 
cell population and irreproducible results.  Previous attempts to control 
isomerisation of ATRA include the use of additives iv which inhibit either cis-trans 
interconversion or oxidation.34  However,  none has been found to completely 
prevent isomerisation and the additives may themselves affect cell behaviour.   A 
more successful solution has been found in the use of stable,  non-isomerisable,  
synthetic retinoids.   
 
 
                                                 
iv Such as bovine serum albumin, fibrogen, lysozyme, phosphatidylcholine N-
ethylmaleimide and vitamin C 
13 
  
1.3 Developing Synthetic Derivatives of Natural Retinoids  
  
It is a recurrent theme throughout the applications described previously that the 
problems incurred with the use of natural retinoids are frequently attributed to 
either lack of receptor specificity,  propensity for metabolism and / or 
susceptibility to isomerisation in both natural light and physiological conditions. 
 
The key functionalities of ATRA and other natural retinoids are susceptible to 
isomerisation.  ATRA and its isomers have a polyene chain containing five 
conjugated double bonds,  which is important in maintaining π-electron 
delocalisation across the molecule.  However,  this structure is an excellent 
chromophore,  absorbing light in the region of 300-400 nm.  Therefore,  natural 
retinoids readily undergo photo-isomerisation in the presence of fluorescent light.  
This leads to a mixture of geometric isomers,  each inducing very different 
biological effects. 
 
 
 
Figure 4:  Illustration of the different units which comprise a retinoid. 
OH
O
Hydrophobic 
unit
Linker unit Polar
Terminus
ATRA
Schematic Retinoid
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A retinoid can be thought of as comprising of three units, a hydrophobic end 
group,  a linker region and a polar terminus (See Figure 4).  Careful modification 
of these units can result in the formation of new,  synthetic retinoids.  Many 
synthetic retinoids which retain the key functionalities of natural retinoids,  yet are 
resistant to isomerisation and metabolism have been designed36.   
 
 
 
Figure 5: The structure of arotinoids TTNPB and TTNN 
 
 
Synthetic retinoids TTNPB37 and TTNN38 shown in Figure 5 are functionally 
similar to ATRA,  however,  contain an a 1,1,4,4,-tetramethyl-1,2,3,4-tetrahydro-
naphthalene moiety in place of the trimethylcyclohexenylvinyl unit,  and the 
conjugated double bond linker is replace by stilbene or biaryl respectively.  
TTNPB and TTNN exhibit both high stability and high biological activity.   
  
 
 
 
 
 
 
OH
OO
OH
TTNPB TTNN
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Figure 6:  Synthetic retinoids Am80 (top), Am580 (middle), and 
Ch55 (bottom). 
 
Synthetic retinoids Am80,  Am580 and Ch55 have also been developed.  
Again,  structural modifications have been carried out to introduce stability 
to the molecule whilst retaining key functional components of ATRA.  
Am80 and Am580 contain the same hydrophobic end group and polar 
terminus as TTNPB and TTNN,  but differ in that they contain an amide 
linker region.  Chick limb bud experiments have shown them to have 
similar biological activity to ATRA.45(This is elaborated on in the following 
section). 
 
 
 
N
H
O
COOH
H
N
COOH
O
O
COOH
16 
  
 
 
Figure 7:  Natural retinoids ATRA and 13cisRA and their synthetic 
derivatives, arotinoids EC23 and EC19.  The para / meta positioning 
of the carboxylic acid group in EC23 and EC19 reflects the spacial 
positioning of the carboxylic acid group in ATRA and 13cisRA 
respectively. 
 
EC23 and EC19 are recent additions to the synthetic retinoid collection.  Again, 
they contain the same hydrophobic end group and polar terminus as TTNPB and 
TTNN,  but in these cases,  the linker unit is a non-isomerisable acetylene unit.  
The general structures of ATRA and 13cisRA were replicated by placing a 
carboxylate function in the para- (EC23) and meta- (EC19) positions of the 
aromatic ring respectively.34 (See Figure 7.)  As with the other synthetic retinoids 
discussed in this section,  EC23 and EC19 exhibit both high stability and high 
biological activity.   
 
NMR studies have shown that EC23 and EC19 are stable in natural light.   They 
remain completely unchanged even after three weeks exposure to fluorescent 
light.34  In comparison,  their natural counterparts ATRA and 13cisRA undergo 
substantial isomerisation such that within 3 days exposure less than 40% of the 
COOH
ATRA
 EC23
13cisRA
 EC19
COOH
COOH
COOH
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original compound remains.34 
 
Biological studies carried out demonstrate that EC23 and EC19 possess the 
ability to induce differentiation of human pluripotent stem cells to the same 
degree or better than that observed for ATRA and 13cisRA.34  EC23,  like ATRA,  
induces neural tissues; whereas, EC19 behaves like 13cisRA in that it induces 
epithelial cells.  Subsequent proteomic studies support these findings that the 
biological behaviour of EC23 and EC19 mimics that of ATRA and 13cisRA 
respectively.39  Preliminary evidence is suggesting that the difficulties 
encountered with the use of natural retinoids may be mitigated through 
replacement with more stable,  synthetic analogues. 
 
1.4 Chick Limb Development 
 
Studies have shown that EC23 and EC19 are more potent than their natural 
analogues.  This may be attributed to the inherent stability of the synthetic 
retinoids.  It is well documented that natural retinoids are metabolised by the 
body8 and it is believed that this metabolism plays a large role in problems with 
their use,  such as the rapid build up of resistance to retinoid therapies,  and to 
the reduced potency of natural retinoids when used as stem cell derivatising 
agents.  It is hypothesised that the body is unable to metabolise EC23 or EC19 
and study was devised to test this hypothesis in vivo.  The following introduction 
to proposed models of limb bud development is to help contextualise the study 
carried out. 
 
The chick limb bud has previously been used to demonstrate the teratogenicity 
and potency of EC23 and EC19.63  It is a good system in which to investigate 
retinoid effects as it is easy to access,  its natural development has long been 
studied therefore it is fairly well understood, and it facilitates quantitative analysis 
of the teratogenic and toxic effect of the compounds studied.   
18 
  
 
There are three orthogonal axes to consider in the chick limb bud.  The 
proximodistal axis runs from the shoulder to the tip of the digits;  the 
anteroposterior axis runs from digit 2 to digit 4 (the equivalent of thumb to little 
finger in humans); and the dorsoventral axis runs from the back of the wing to the 
front (equivalent to back of the hand to the palm in humans).  Chick limbs,  like all 
vertebrate limbs,   develop from small buds of mesenchyme cells.  The cells are 
specified to form limb digits long before they actually do.  As they grow the cells 
differentiate into the various tissues of the limb.40  
 
There are two main stages of pattern formation.  In the first stage, specification,  
the cells are informed of their position and acquire what is known as a positional 
value.  During the second stage,  differentiation,  the cells then interpret this 
value to form the appropriate structures.41  
  
Anteroposterior, proximodistal and dorsoventral patterning are regulated by 
distinct but interdependent pathways.  For a discussion of how these models may 
be interlinked,  see the recent review by Towers and Tickle.41  Growth also plays 
an essential role in the specification of positional values in the early limb bud and 
a recent growth/morphogen model of chick wing pattering has been discussed by 
Towers et al.42  For simplicity, the rest of this introduction will focus on 
anteroposterior patterning. 
 
The Morphogen Gradient Model 
This classical model proposes that a group of mesenchyme cells at the posterior 
limb bud margin,  known as the zone of polarizing activity (ZPA), produce a 
morphogen which diffuses across the limb bud,  creating a diffusion gradient.  In 
regions where the morphogen concentration is high,  i.e. close to the polarizing 
region,  the cells will form posterior digits.  As the distance the cells are from the 
19 
  
ZPA decreases,  the morphogen concentration decreases and the cells 
progressively form more anterior digits.43,41  In the normal chick limb,  the digits 
are formed in a 234 pattern.   
 
A concentration gradient of ATRA plays an important role in the pattern formation 
of digits 
Both the Shh gene and ATRA are thought to play important roles in the pattern 
formation of digits.  ATRA may be synthesised enzymatically in the posterior 
tissue from retinol and is thought to form a concentration gradient along the AP 
axis.44  Several experiments which demonstrate the roles of the ZPA and ATRA 
in digit patterning have been carried out.  
 
The ZPA and dHAND are important in digit pattern formation 
When the ZPA is removed from the limb bud no digits form.45   Grafting tissue 
taken from the ZPA of one limb bud to the anterior margin of another limb bud 
gives rise to a symmetrical 4 3 2 2 3 4 digit pattern.41  This is evidence that the 
ZPA is important in instructing digit pattern in developing limbs. 
 
dHAND, a basic helix-loop-helix transcription factor also plays an important role 
in regulation of digit development.  It is expressed during the onset of limb bud 
outgrowth, and is localised in the posterior region of the limb bud.  Studies have 
shown it to be an upstream activator of Shh expression and a regulator of limb 
development.46  Embryos devoid of dHAND show underdeveloped limbs and 
those with ectopic expression in the anterior region show digit duplication.  
 
Evidence that a morphogen is important in controlling digit pattern formation 
Application of ATRA to the anterior margin of the limb bud also gives rise to a 
symmetrical 4 3 2 2 3 4 digit pattern.41  A diagram of the procedure can be seen 
in Figure 8.  The extent of digit duplication was found to be dependent on the 
concentration of ATRA applied47 showing that the limb bud can be used to 
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assess quantitatively the potency of retinoids.v  The position at which the 
exogenous ATRA is applied is important.  When ATRA was applied to the 
posterior margin of the limb bud at concentrations that would induce digit 
duplication when applied to the anterior, normal digit patterning was seen.  This 
supports theories that a concentration gradient is necessary in determining 
normal digit patterning and that disrupting this leads to abnormal digit growth. 
 
Figure 8:  Application of a polymer bead soaked in retinoid solution applied 
to the anterior margin of the limb bud may affect the concentration gradients 
occurring naturally in the developing limb. 
 
Application of certain synthetic retinoids to the anterior margin of the limb bud 
can also give rise to a symmetrical 4 3 2 2 3 4 digit pattern. 
Synthetic retinoids Am80, Am580  and Ch55, shown in Figure 6, also mimic the 
action of ATRA when applied to the anterior margin of the limb bud.45  The extent 
of digit duplication was shown to increase progressively (i.e. 3234, 43234, 
432234, 4334) as the retinoid concentration was increased from 0.001 to 1.000 
mg/ml.  The effective dose necessary to produce each effect was similar to that 
required of ATRA.  Interestingly,  when these synthetic retinoids were applied to 
the anterior margin of a ZPA-free limb bud (i.e. ZPA had been removed), a 
                                                 
v It should also be noted that the speed at which retinoids are released from the bead 
also affect the extent of digit duplication seen.62  
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reverse digit pattern was observed (432).45 
 
EC23,  a synthetic analogue of ATRA,  has been evaluated in the chick limb bud 
system and was also found to produce the 432234 phenotype at concentrations 
of 0.1 mg/ml (shown in Figure 9).  Concentrations above 1.0 mg/ml were found to 
be toxic.  EC19 was also investigated and found to induce collapse of facial 
features (shown in Figure 9).  As found in the stem cell differentiation studies, 
EC23 shows very similar biological effects to ATRA,  but is much more potent.48 
 
 
 
Figure 9: Previous results from chick limb bud investigations carried out by 
insertion of a loaded AG1-X2 polymer bead into to the anterior margin of 
the limb bud of a stage 20 chick embryo.  The above images show the 
development observed at stage 36. Left: Control. Limb showing normal, 
234 development after being treated with a saline soaked bead. Middle: 
Embryo limb showing 432234 digit pattern after being treated with a bead 
soaked in 0.1 mg/ml EC23; Right: Facial disfiguration caused by the 
insertion of a bead soaked in 0.1 mg/ml EC19 solution (DMSO) 48 
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Investigation into Metabolism of Retinoids 
 
 
 
Scheme 2:  Left hand side: A schematic showing the metabolism of AT-retinol to 
ATRA,  via AT-retinal.  There is much evidence that this occurs.  Right hand 
side:  It is currently believed that the body is unable to metabolise synthetic 
retinoids such as EC23 along the same route as its natural analogue. 
 
It is hypothesised that the body is unable to metabolise EC23,  due to its robust 
structure and resistance to isomerisation.  If correct,  this could explain its 
increased potency compared to that of ATRA.  The following study was devised 
to test this hypothesis.  It is known that the body is able to enzymatically convert 
AT-retinol to ATRA,49 and that when suitable concentrations of ATRA are applied 
to the anterior margin of the limb bud the result is digit duplication.  It was thus 
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hypothesised that if  retinol was applied exogenously to the anterior margin,  it 
would be converted to ATRA and thus cause digit duplication.  An extension of 
this reasoning would be to apply the synthetic derivative of retinol,  EC23-OH,  
(see Scheme 2) to the anterior margin of the limb bud and look for abnormal 
phenotypes.  If the body is able to metabolise EC23-OH,  it would be expected it 
would be converted to EC23 and hence digit duplication would occur.  If, 
however, as is predicted, normal develpment is observed, this would provide 
further evidence that EC23 is refractory to normal retinoid metabolism. In order to 
test this hypothesis, the effects of natural retinol on the limb bud had to be 
evaluated and the synthetic equivalent,  EC23-OH,  had to be synthesised.   
 
1.5 Synthetic Strategy: Pd-Catalysed Cross-Coupling 
 Reactions 
 
Pd is one of the most versatile,  powerful and widely used transition metal 
catalysts.  Pd is in group 10 of the periodic table and is therefore an electron rich 
transition metal.  Pd complexes can exist in three different oxidations states 0, II 
and IV,  and interconversion between them is often facile.  This,  along with the 
fact it can support different coordination numbers,  enables Pd to be a catalyst.  It 
is widely used in the synthesis of many functionalised organics used for wide 
ranging applications from liquid crystals to biologically active molecules which will 
be discussed in this report. 
 
Despite recent debate, it is generally believed that Pd(0) is the active catalytic 
species.  This can either be obtained directly from a source of Pd(0),  e.g. 
Pd(PPh3)4, or can be formed in situ by reduction of a Pd(II) source such as 
Pd(PPh3)2Cl2.  The latter approach is normally used as generally Pd(II) sources 
are soluble in most organic solvents and fairly stable towards air and moisture, 
making them easier to handle and store than Pd(0). 
Over the years, many variations of Pd-catalysed cross-coupling systems have 
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been developed such as Suzuki-Miyaura, Heck, Stille, Negishi, Sonogashira, etc.  
However, they are all mechanistically similar and follow a catalytic cycle 
comprising oxidative addition, transmetallation and reductive elimination (see 
Scheme 3). 
 
 Scheme 3: Generic catalytic cycle for palladium-catalysed  cross-coupling 
 reactions.  
 
If a Pd(II) catalyst precursor is used, it must first be reduced to form a 
nucleophilic Pd(0) species.  It is not fully understood how this mechanism occurs 
for each different cross coupling reaction, but it has been thoroughly studied for 
the Sonogashira reaction and will be discussed briefly later. 
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Oxidative Addition 
The first step in the catalytic cycle is oxidative addition of Ar-X (where Ar is 
generally an aryl, vinyl or allyl and X is a halide or triflate) to the Pd(0) catalyst to 
form an electrophilic Pd(II) intermediate.  In the past, this was usually the rate 
determining step of the cycle so much work has been done to increase the rate 
of oxidative addition.  For example, optimisation of the donor ligands leads to 
increased electron density on the Pd centre, increased nucleophilicity and 
therefore an increased rate of oxidative addition.  For example, tBu3P has proved 
to be an excellent ligand, and facilitates the reaction of otherwise unreactive, or 
very slow reacting reagents such as aryl chlorides.50  tBu3P is strongly donating, 
which promotes oxidative addition, yet bulky which helps promote reductive 
elimination.vi  Choice of Ar-X substrate also influences the rate; this is briefly 
elaborated on later.   
 
Transmetallation 
The Pd(II) intermediate formed during the oxidative addition step then reacts with 
a nucleophilic organometallic reagent, M-R‟, to form a diorganyl-palladium(II) 
species via transmetallation.  The M-X salt formed simultaneously is the 
thermodynamic driving force for this reaction.  It is generally the transmetallation 
step that differs between the different cross coupling-reactions, and the choice of 
metal used determines the name of the reaction.  For example, in the 
Suzuki-Miyaura reaction,  M = B(OR)2 whereas in the Sonogashira reaction, a 
copper acetylide is used. 
 
                                                 
vi
 It is important to maintain a balance – whilst electron donating ligands promote oxidative addition; 
bulky, electron withdrawing ligands facilitate reductive elimination.  A balance must therefore be 
struck as both processes are essential to the catalytic cycle. 
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Reductive Elimination 
The final step is reductive elimination.  During this step the two organic fragments 
are joined by the formation of a new bond and the Pd(0) catalyst is regenerated.  
This is believed to be a concerted process and in order for it to happen a trans-
cis isomerisation must first occur to align the two fragments. 
 
The Sonogashira Reaction 
The palladium-catalysed cross-coupling of terminal alkynes with aryl halides was 
first reported in 1975 independently by the groups of Cassar51 and Heck.52  
Shortly after, Sonogashira et al. reported an improvement to the reaction by the 
addition of Cu(I) salts, which allowed the reaction to proceed under mild 
conditions.53  Scheme 4 shows the proposed catalytic cycle.  Further 
improvements and modifications have been made over the years and it is now an 
important route to many organic compounds.   It is a key route to alkyne 
containing synthetic retinoids. 
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 Scheme 4:  Proposed Catalytic Cycle for the Sonogashira  Cross- Coupling 
 Reaction [adapted from Sonogashira et al.53] 
 
Unless a practicality requires the direct use of a Pd(0) catalyst,  Pd(II) 
precursorsvii are generally used for the Sonogashira reaction.  They are reduced 
                                                 
vii Pd(II) complexes are generally much more stable to air and moisture that Pd(0) complexes and are therefore 
easier to handle. 
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in situ to Pd(0) before the catalytic cycle can begin.  This mechanism has been 
studied extensively54 and is well understood for the Sonogashira reaction.  
Generation of the active catalyst Pd(0) is achieved by transmetallation of two 
equivalents of terminal Cu-acetylide to Pd(II) followed by reductive elimination.  
CuI facilitates the deprotonation of a terminal alkyne by an amine to give Cu-
acetylide in situ.  Two equivalents of Cu-acetylide are then exchanged for the two 
halide ligands on the Pd centre.  Trans-cis isomerisation followed by reductive 
elimination of one equivalent of homocoupled diyne generates the active catalyst 
Pd(0). Generally, it is a facile process to separate the homocoupled from the 
desired product during purification.  If  however, this would be difficult, e.g. if the 
two compounds had very similar polarities, then the direct use of a Pd(0) catalyst 
would be advised. 
 
Much work has also gone into the study of the oxidative addition step.  It is well 
documented that the rate of oxidative addition of an aryl halide to a Pd catalyst is 
correlated to the strength of the C-X bond, with weakly bound C-I having a high 
rate of reaction in comparison to more strongly bound C-Cl.  Also, the presence 
of electron withdrawing groups para to the halide, further increases the rate of 
oxidative addition. The mechanism of oxidative addition was examined 
theoretically with the aid of DFT calculations in a recent study by Lam, Marder 
and Lin.55   
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Chapter 2:   Chemical Synthesis, Results  
and Discussion 
 
2.1 Synthesis of Starting Materials 
 
Aryl boronic acids and esters are versatile reagents in organic synthesis for the 
formation of carbon-carbon,  carbon-nitrogen and carbon-oxygen bonds.  They 
are especially useful for cross coupling reactions as they generally have high 
stability and low toxicity.  The compound 4,4,5,5-tetramethyl-2-(5,6,7,8-
tetrahydronaphthalene-2-yl)-1,3,2-dioxaborolane (1) was made for use as a 
precursor to synthetic retinoids. 
 
 
Scheme 5:  Synthesis of retinoid precursor 4,4,5,5-tetramethyl-2-(5,6,7,8-
tetrahydronaphthalene-2-yl)-1,3,2-dioxaborolane (1).  a) 1 eq. B2pin2, 
2% Pd(OAc)2 / 5% S-phos,  2 e.q. K3PO42H2O,  dioxane, 80 °C   
 
Buchwald conditions were utilised to prepare 1 from 6-(4-Bromo-phenylethynyl)-
1,1,4,4-tetramethyl-1,2,3,4-tetrahydro-naphthalene (bromo-TTNPB) (See 
Scheme 5).  Buchwald reported that the ligand s-phos,  (shown in Figure 10) 
facilitates the palladium catalysed borylation of aryl chlorides at room 
temperature.56  As aryl bromides are generally more reactive than aryl chlorides,  
it was could be expected that the reaction of bromo-TTNPB would occur readily 
at room temperature.  However,  it had been found previously to take two weeks 
of room temperature stirring followed by a further week of heating at 60 °C before 
B
O
O
Br
a
1
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complete borylation of bromo-TTNPB was observed by GC-MS.  It was therefore 
decided to carry out the reaction at 80 °C in order to speed up the reaction time.  
GC-MS analysis showed 60% consumption of starting materials after 18 hours,  
and this increased to 80% after the reaction had been left to continue for 48 
hours.     
 
 
Figure 10: Structure of Buchwald‟s S-phos ligand.  
 
The aryl boronic ester, 4,4,5,5-tetramethyl-2-(5,6,7,8-tetrahydronaphthalene-2-
yl)-1,3,2-dioxaborolane 2,  was also synthesised for future use as a retinoid 
precursor. 
 
 
Scheme 6:  Synthesis of retinoid precursor 4,4,5,5-tetramethyl-2-(5,6,7,8-
tetrahydronaphthalene-2-yl)-1,3,2-dioxaborolane 2.  b)  1 e.q. B2pin2,  1 % 
[Ir(OMe)(COD)]2 / 2 % dtbpy,  hexane,  80 °C  / N2 
 
As [Ir(OMe)(COD)]2 / dtbpy
 is known to be effective catalyst for borylation of 
heteroaromatic substrates,57 it was used to borylate tetrahydronaphthalene  (see 
Scheme 6).  The reaction proceeded cleanly and was shown to have gone to 
completion by GC-MS analysis after being stirred for 18 hours at 80 °C.  The 
product was separated from the reaction mixture by passing through a short 
MeO OMe
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O
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silica plug with a mixture of dichloromethane and hexane.  Once the solvent was 
removed,  a transparent oil remained.  This was crystallised from methanol at 
-20 °C as colourless needles.  A yield of 93% was obtained.  Boron,  proton and 
carbon NMR confirm the identity of 2 and the crystal structure is shown in Figure 
11,  below. 
 
 
 
Figure 11:  Molecular structure of 4,4,5,5-tetramethyl-2-(5,6,7,8-
tetrahydronaphthalene-2-yl)-1,3,2-dioxaborolane  2. 
 
Acetic acid 4-bromo-benzyl ester (3) is a starting material for the benzyl-alcohol 
equivalent of EC23.  It was synthesised from 4-bromobenzyl bromide and 
potassium acetate using a method adapted from a paper by Wolfe et al,58  as 
shown in Scheme 7.  4-bromobenzyl bromide was reacted with potassium 
acetate in acetonitrile.  After 5 days GC-MS analysis showed the reaction had 
gone to completion.  No complications were encountered and a yield of 87% was 
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obtained.  Full characterisation was carried out and the crystal structure is shown 
in Figure 12 below. 
  
 Scheme 7:  Synthesis of acetic acid 4-bromo-benzyl ester (3);   
 c) MeCN, reflux, N2, 24 h.  
 
 
 
 Figure 12: Molecular structure of acetic acid 4-bromo-benzyl ester (3).  
 
6-Ethynyl-1,1,4,4-tetramethyl-1,2,3,4-tetrahydronaphthalene (TMNA) is a key 
starting material for synthetic acetylenic retinoids.  It is not yet available 
commercially,  but a synthesis from an aryl methyl ketone has previously been 
reported by Wuest et al.59  A more straightforward synthesis from commercially 
available 1,1,4,4-tetramethyl-2,2,3,3-tetrahydronaphthalene has been developed 
Br
O
O
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in the Marder lab,  as shown in Scheme 8.  It was synthesised in bulk prior to 
further retinoid synthesis. 
 
Scheme 8: Synthesis of TMNA (4).   d) 1.2 eq. TMSA, 1% Pd(PPh3)2Cl2, 1% 
CuI, Et3N;  e) 4 eq. Na2CO3, MeOH/10% H2O   
 
The reaction of 6-iodo-1,1,4,4-tetramethyl-1,2,3,4-tetrahydronaphthalene and 
trimethylsilyl was catalysed by Pd(PPh3)2Cl2 and copper iodide in dry 
triethylamine.  The reaction went to completion at room temperature within 18 
hours.  The reaction mixture turned dark brown / black,  but most of the colour 
was removed on extraction with dichloromethane to give a 72% yield of a pale 
orange crystalline solid.  GC-MS and NMR spectra are consistent with those 
expected.  In the 1H NMR spectra, the doublet seen at δ 1.29 integrating to 12 
protons is typical of the CMe2 groups of the TMNA moiety.  The three peaks seen 
in the aromatic region are consistent with being the three aromatic protons and 
the singlet at δ 3.02 corresponds to the H-C≡C proton.    
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2.2 Retinoids from Suzuki-Miyaura Cross-coupling  
 
 
Figure 13:  Methyl 5',6',7',8'-tetrahydro-2,2'-binaphthyl-6- carboxylate (5) 
and (E)-methyl 3-(4-(5,6,7,8-tetrahydronaphthalen- 2-yl)phenyl)acrylate (6). 
 
The synthesis of compounds methyl 5',6',7',8'-tetrahydro-2,2'-binaphthyl-6-
carboxylate (5) and (E)-methyl 3-(4-(5,6,7,8-tetrahydronaphthalen-2-
yl)phenyl)acrylate (6), shown in Figure 14, was attempted in order to add these 
compounds to our growing library of retinoids and to be tested for biological 
activity.  They possess several of the key moieties necessary for retinoid activity, 
such as a polar terminus and a system of conjugated double bonds.  However,  a 
key difference between these molecules and other known retinoids such as 
ATRA, EC23 and TTNPB37 (discussed in section 1.3),  is that they do not 
possess CMe2 groups on the naphthalene ring.  It is thought that the CMe2 
groups are involved in receptor binding36 and it would therefore be of interest to 
investigate the biological activity of structurally similar molecules with the 
absence of these groups. 
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 Scheme 9:  Synthesis of methyl 5',6',7',8'-tetrahydro-2,2'-binaphthyl-6-
 carboxylate (5)  f) 2% Pd(dppf)Cl2, 2 eq. K3PO4,  5:1
iPrOH/H2O, 80°C 
 
Suzuki-Miyaura conditions were utilised to couple 2 with methyl-6-bromo-2-
naphthoateviii to form 5 (see Scheme 9).  GC-MS analysis showed some product 
had formed after four hours.   After five days an orange / brown solution had 
formed and GC-MS analysis showed that the reaction had gone to completion.  
The volatiles were removed and the organic product was extracted into 
dichloromethane.  Further removal of volatiles yielded the product as a yellow 
solid.   1H NMR and GC-MS analysis showed that 5 had been made but that it 
was impure.  Flash chromatography with dichloromethane and hexane 
significantly improved the purity.  The number and size of impurity peaks was 
reduced considerably and elemental analysis results agreed to within 0.7% of 
those calculated.      
 
 
                                                 
viii Methyl-6-bromo-2-naphthoate is available commercially, CAS# 3362-98-1 
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Scheme 10:  Synthesis of (E)-methyl-3-(4-(5,6,7,8-tetrahydronaphthalen-2-
yl)phenyl)acrylate (6) showing homocoupled by-product.  g) 2% Pd(dppf)Cl2, 
2 eq. K3PO4,  5:1
iPrOH/H2O, 80°C. 
 
2 was also coupled with (E)-methyl 3-(4-bromophenyl)acrylate, again using 
Suzuki-Miyaura conditions, to form 6.  (see Scheme 10).  GC-MS,  1H and 
13C NMR analysis confirmed that 6 had been made.  However small additional 
peaks in the spectra indicate traces of an impurity.  Flash chromatography using 
dichloromethane/hexane increased the purity; however, the yield was reduced to 
5% and small impurity peaks remained.  Inspection of the GC-MS spectra 
showed the impurity had a mass of 320, suggesting it was likely to be the 
homocoupled product of the boronate ester (shown in Scheme 10).  Time 
constraints prevented further attempts at purification;  however, a less polar 
solvent system, such as hexane/ether or hexane/ethyl acetate may lead to 
greater success in isolating 6 from the homocoupled product in the future. 
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2.3 Route to Benzyl Alcohol 
 
 
 
 
 Figure 14:  EC23-OH (left) and EC19-OH (right); Benzyl alcohol 
 analogues of EC23 and EC19 respectively. 
 
 
In order to determine whether or not synthetic retinoids EC23 and EC19 can be 
metabolised in the same manner as the naturally occurring retinoid ATRA, as 
discussed in the introduction,  it was necessary to first synthesise the benzyl 
alcohol analogues,  EC23-OH and EC19-OH (Figure 14) which could then be 
tested in the chick-limb system. 
 
It had previously been thought that EC23-OH and EC19-OH could be made 
simply by a reduction of the methyl esters of EC23 and EC19 respectively.  High 
conversions (100% by GC-MS) were obtained using lithium borohydride in 
diglyme at 80 °C.  However,  work up proved difficult and only low yields were 
obtained,  so a new approach was taken. 
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Readily available starting materials were instead used to synthesise EC23-OAc 
and EC19-OAc with the intent that they could then be easily hydrolysed to EC23-
OH and EC19-OH respectively when needed.  The direct synthesis of EC23-OH 
and EC19-OH was considered,  however previous experience has shown that 
ether acetate analogues have the advantage of being easier to work up and 
purify. 
 
 
 
 Scheme 11: Proposed synthesis of EC23-OH, via EC23-OAc (7).  
 h) 1 %  Pd(PPh3)2Cl2, 1 % CuI, Et3N, 80°C, 2 d; i) Hydrolysis. 
 
A Sonogashira reaction was employed to couple 4 with acetic acid 4-
bromobenzyl ester (see Scheme 11) to form EC23-OAc (7).  GC-MS analysis 
showed that complete consumption of starting materials was achieved within 24 
hours at 80 °C using a 1% Pd(PPh3)Cl2/CuI in Et3N catalyst system. The volatiles 
were removed from the resulting black solution to give a tan coloured solid.  This 
was purified using flash chromatography, eluting with DCM/Hexane. The final 
yield of pure product was only 1 % - Much lower than expected for this type of 
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coupling reaction.  It is believe that much product was lost in purification.  If 
repeated, a different solvent system should be used to elute. Crystals obtained at 
room temperature in DCM were analysed by x-ray diffraction, which confirmed  
them to be the desired compound, crystal structure shown in Figure 15)  13C and 
1H NMR spectra also conform to that expected for 7 and elemental analysis 
agrees to within 0.5% of that calculated.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure  15:  Molecular structure of EC23-OAc   
[4-((5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)ethynyl)benzyl 
acetate]. 
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 Scheme 12: Proposed synthesis of EC19-OH, via EC19-OAc (8).  
 j) 1 %  Pd(PPh3)2Cl2, 1 % CuI, Et3N, 21°C, 2 d; k) Hydrolysis. 
 
Another Sonogashira reaction was employed to couple the iodide precursor,  
acetic acid 3-iodo-benzyl ester with 4 to synthesise EC19-OAc,  as shown in 
Scheme 12.  The same catalyst system was used as for the previous reaction;  
however,  in this case the aryl iodide was sufficiently electrophilic to react at room 
temperature.  GC-MS analysis revealed that complete consumption of starting 
materials was achieved within 21 hours.  After washing the crude product 
through a silica plug with Et2O,  tlc analysis showed that two compounds were 
still present.  These were separated using a silica plug, eluting first with hexane, 
and then with hexane/Et2O (1:5).  Removal of the solvent yielded 30 % yield of a 
pale orange / brown solid.  It is likely that some product was lost during 
purification, and expected that this yield could be improved upon.  Full 
characterisation has been carried out and HR-MS measured an excellent mass 
accuracy of 0.06 ppm!  
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Chapter 3:   Biological Results and Discussion 
3.1 Serial Dilution of Retinoid Solutions  
 
The volumes and concentrations of retinoid solutions required for the 
investigations were small and low.  Precision in measuring was therefore crucial 
and a serial dilution was carried out to determine pipetting accuracy.  This was 
performed using 0.1 mg/ml solutions of EC23 and AT-retinol in DMSO.  [See 
section 6.2 for procedure details.]  A NanoDrop spectrophotometer was used to 
measure the absorbance of the diluted solutions at λ = 305 nm and λ = 335 nm 
for EC23 and AT-retinol respectively.  Both series gave straight lined graphs (see 
Figures 16 and 17 below), showing that the pipette can be used to accurately 
make up solutions with concentrations as low as 0.0016 mg/ml (0.467 x 
10-5 moldm-3). 
  
Figure 16:  Serial dilution of EC23. Solutions were made up at a range of 
concentrations from 0.10000 mg/ml to 0.00156 mg/ml.  The absorbance (A) 
of each solution at λ = 306 nm was measured and plotted against 
concentration.  R2  (the coefficient of determination)ix was calculated to be 
0.99, showing excellent agreement between the concentration and the 
absorbance measured, confirming pipetting accuracy. 
                                                 
ix R2 (the coefficient of determination) returns a value between 1 and 0, where 1 
corresponds to complete correlation of data and 0 implies no correlation at all. 
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Figure 17:  Serial Dilution of AT-retinol.  Solutions were made up at a 
range of concentrations from 0.10000 mg/ml to 0.00156 mg/ml.  The 
absorbance (A) of each solution at λ = 335 nm was measured and 
plotted against concentration.  R2  (the coefficient of 
determination)Error! Bookmark not defined. was calculated to be 
0.98, showing excellent agreement between concentration and the 
absorbance measured, confirming pipetting accuracy. 
 
3.2 Development of Procedures for In Vivo Analysis of 
 Retinoid Action 
 
The procedure used to apply retinoids to the chick limb bud is technically 
challenging,  due to the small scale and delicacy of the embryo.  Therefore a 
significant amount of practice is required to become competent in this technique.  
It is important the operation is performed when the embryo is at stage 20 of the 
Hamburger and Hamilton60 staging system as this is the critical period at which 
the chick limb bud is susceptible to malformation by teratogens5 such as ATRA.  
First,  forceps are used to remove the outer shell to create a window through 
which the embryo can be viewed and accessed.  Great care must be taken to 
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apply just enough force to break through the tough outer shell, whilst leaving the 
membrane intact to protect the embryo from falling shell.  The outer membrane is 
then peeled back to reveal the embryo.  Biological saline containing nutrients,  
antibiotics and antimitotics is applied and the egg is placed under a microscope.  
A further two membranes are cleared using a tungsten tipped needle, before 
access to the limb bud is gained.  The needle is then used to cut a slit, 
approximately 220 µm in length (fractionally longer than the diameter of the 
bead) along the anterior margin of the limb bud.  Fine forceps are used to insert 
an AG1-X2 bead into the opening and gentle pressure is applied to ensure it is 
securely embedded.  The embryo is observed for a few seconds to ensure the 
bead and limb-bud move up and down together when the heart beats.  This is an 
indication of successful bead attachment.  The egg is quickly sealed with 
“Sellotape Original”,™x then returned to the incubator for 7 days.  It is essential to 
ensure a complete seal around the opening – this prevents the embryo from 
drying out and also provides protection from infection.  The whole procedure 
should be carried out quickly and carefully.  The faster the operation,  the greater 
the chance of survival.    
 
Beads soaked in biological saline were used initially whilst practicing the 
technique.  The embryos developed normally,  showing that neither the act of 
carrying out the operation nor insertion of a bead causes digit duplication.  The 
abnormal effects seen in other experiments can therefore be attributed to the 
retinoid applied.  However,  it is important to use spherical beads, as previous 
studies have shown the implantation of irregular shaped beads can cause 
malformation.   
 
21 operations were carried out using 0.1mg / ml retinol in DMSO.  2 embryos 
survived to examination and were found to have successfully attached beads.  
They both showed normal development.  A further 3 embryos survived to stage 
                                                 
x Other types of tape were found to be much less effective.  Sellotape Original was found 
to give the best seal of the tapes tried and therefore the highest survival rate. 
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24 or beyond and also all showed signs of normal development.  9 embryos 
became infected and / or died before reaching stage 24, and were not yet 
advanced enough in development to analyse.  The remaining embryos were 
found to have either the bead attached in the wrong position,  or that it had 
migrated elsewhere in the embryo and were therefore discounted in the study.   
 
In summary,  10 embryos containing correctly positioned beads soaked in 
0.1 mg/ml AT-retinol survived to a suitable age to assess accurately their 
development.  They all exhibited normal development,  suggesting that under 
these conditions,  0.1 mg/ml AT-retinol does not cause digit duplication when 
applied anteriorally to the limb bud.  This result was surprising as AT-retinol is a 
potent teratogen61, documented to induce severe birth defects when ingested by 
pregnant mice.  These results appear to suggest that AT-retinol does not induce 
teratogenic effects when applied to this region of the limb bud;  however, 
alternative explanations include the possibility that the beads may not be 
delivering AT-retinol to the limb-bud or that the concentration of AT-retinol used 
may be too low to cause an effect.  These later possibilities must be investigated 
before conclusions can be drawn. 
 
In order to see if a higher concentration of AT-retinol may cause an effect, a 
further 14 operations were carried out using 1.0 mg/ml AT-retinol.  All of the 
embryos surviving to stage 24 or beyond, with correctly positioned beads showed 
normal development.  Again, this is a surprising result,  as it was expected this 
high concentration of retinol would be toxic.  Further investigation into whether or 
not the beads were delivering retinol was required.  
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3.3 Loading and Unloading Assays 
 
AG1-X2 beads consist of a styrene-divinylbenzene cross-linked lattice with 
attached quaternary ammonium groups.  They act as ion exchange beads and in 
solution the electrostatically bound formate ions are exchanged for polar 
molecules such as ATRA,62  EC23 and EC19.  Thaller and Eichele used 
chromatography to demonstrate that AG1-X2 beads deliver radioactive AT-retinol 
to the limb-bud and that it is then converted to AT-retinal and ATRA.49  AG1-X2 
beads have also been used successfully in our group to deliver ATRA, EC23 and 
EC19 to chick limb-buds and digit duplications have been recorded.63  It should 
therefore be reasonable to expect the beads to deliver AT-retinol. 
 
Loading and unloading assays were carried out in triplicate to assess whether or 
not retinol was being taken up by the beads and delivered to the embryos.  A 
fresh solution of 0.1 mg/ml AT-retinol was made up using spectroscopic grade 
DMSO, to ensure impurities from the solvent would not interfere with the results.  
(In vivo experiments were carried out using retinoid solutions made up in 
biological grade DMSO).  The beads were soaked in the retinol solution and 
5 µm aliquots were removed at regular time intervals.  The samples were 
quenched by freezing to preserve them until they could be analysed 
spectroscopically to assess the concentration of retinol remaining in solution. 
[See section 6.2 for full details of method.] 
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Figure 18:  AT-Retinol loading assay.  40 AG1-X2 beads were soaked in a 
solution of AT-retinol in A.C.S. DMSO.  The absorption measured at λ = 284 
nm appears to decrease over time.   
 
Before analysing the samples, the absorbance of pure A.C.S. DMSO was 
measured.  No peak was observed at λ = 284 nm,  implying any peak observed 
at this wavelength is representative of AT-retinol.  The results are shown in 
Figure 18.  Overall the absorbance at λ = 284 nm appears to decrease over time,  
suggesting the concentration of retinol in solution is decreasing,  indicating that 
the beads are taking up retinol.  However, the increase in absorbance seen 
around 2 hours is inconsistent with the expected results and gives reason to 
question these findings.  Whether or not the beads are taking up retinol is 
inconclusive from these data.  
 
An unloading assay was also performed to assess the release of AT-retinol from 
the beads.  Beads were soaked in 1.0 mg/ml and 10.0 mg/ml retinol respectively 
for 11 days.  The excess retinol solution was removed and replaced with saline.  
5 µl samples were taken at time intervals for spectroscopic analysis.   The results 
are displayed in Figure 19 below and are not as expected for an unloading 
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assayxi (the expected curve for an unloading assay is shown in Figure 20). The 
results are difficult to interpret,  and it is not possible to deduce accurately 
whether or not retinol is being released from the beads.  It is likely that 
isomerisation of retinol is taking place,  and that this is interfering with the results.   
 
 
Figure 19:  AT-Retinol unloading assay.   AG1-X2 beads were soaked in 
AT-retinol in DMSO solution.  The excess solution was removed and 
replaced by fresh DMSO.  The absorbance at λ = 284 nm of samples was 
plotted against time to assess the rate at which retinol is released from the 
beads. 
 
                                                 
xi In a similar investigation, Thaller and Eichele report the amount of compound released 
per unit time increases in direct proportion to the concentration of compound adsorbed by 
the beads.
62 
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Figure 20:  Expected shape of an unloading curve. 
 
A control assay was carried out to show that the peak at λ = 284 nm was from 
the AT-retinol, and was not due to either the beads or the DMSO.   AG1-X2 
beads were soaked in A.C.S. grade DMSO and the absorbance of samples taken 
immediately and at time intervals afterwards were measured.  The absorbance at 
λ = 284 nm was consistently zero.  
 
 
3.4 Effect of EC23 on Chick Limb Development 
 
The results from the loading and unloading assays were inconclusive and an 
alternative way in which to test the beads was sought.  It is known that EC23 
induces significant digit duplication in chick wings,63   so 21 operations were 
carried out using 0.01 mg/ml EC23 (the optimum concentration).  Surprisingly, no 
evidence of abnormal development was observed.  This  unexpected result 
provided  further evidence that the beads were not delivering the compounds to 
the embryos. 
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The previous beads were discarded, and a fresh set of AG1-X2 beads were 
derivatised using formic acid (See section 6.2 for details of procedure).  There 
was no apparent difference in appearance between the old and the new beads. 
 
Operations using 0.01 mg/ml EC23 solution were repeated and carried out within 
2 weeks of the beads being derivatised.  17% of embryos were still alive at the 
point of observation and all clearly showed that a 2,2,3,4 digit pattern had 
developed, i.e.  a second digit 2 had developed.  A further 33% of embryos 
survived until stage 31 and also showed clear duplication of digit 2.  Another 17% 
of embryos also showed signs of digit duplication,  but only survived to stage 27.  
It was therefore too early to be able to accurately determine whether or not 
abnormal development has occurred.  Unfortunately, in one case the bead had 
become attached to the membrane,  so had to be discounted from the study.  
The key results are summarised in Figure 21.  These positive findings show that 
the technique is working and the beads are positioned correctly.  It strongly 
suggests that the previous beads were not delivering retinoids to the limb bud 
and that the beads need to be freshly derivatised frequently. 
 
Embryos showing abnormal development (%) 83 
Embryos observed with 2,2,3,4 digit pattern (%) 50 
  
 Figure 21: Summary of abnormalities observed after the application of 
 0.01 mg/ml EC23 solution to  the anterior margin of a stage 20 chick limb bud.  
 Observations made at stage 36.   
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3.5 Effect of Retinol on chick limb development 
 
A further twenty-seven operations were carried out using freshly derivatised 
beads to deliver 0.1 mg/ml AT-retinol solution to the limb bud.  Seven embryos 
survived to examination,  had correctly positioned beads and yet still all showed 
normal development.  A further six embryos had correctly positioned beads and 
survived beyond stage 24 and also all showed normal development.  As Thaller 
and Eichele assert that AG1-X2 beads are suitable to deliver retinol62, and we 
now have evidence they are successfully delivering EC23, it is highly likely the 
beads are now delivering retinol, yet digit duplication is still not seen.   
 
These results appear to suggest that a concentration of 0.1 mg/ml does not 
induce digit duplication in chick embryos.  However, care must be taken when 
interpreting these findings.  As discussed in the introduction, AT-retinol is very 
unstable in both natural light and physiological conditions, and undergoes 
isomerisation readilyxii.  It is feasible that the retinol underwent isomerisation, in 
solution even before it was applied to the limb buds.  It is therefore not known 
what concentration, if any was delivered to the embryos.  In fact, a major driving 
force behind this project is to develop synthetic retinoids which mimic the 
biological activity of natural retinoids, yet be resistant to isomerisation, in order to 
avoid just these types of problems.  Further investigation is required before firm 
conclusions can be made about the effect of retinol on the limb bud.  
Suggestions are made in “future work” section.  
 
                                                 
xii An NMR study on the stability of ATRA revealed that after only three days exposure to 
ordinary laboratory light, substantial isomerisation / degradation had occurred, such that 
approximately only 37% ATRA remained34. The structure of AT-retinol is closely related 
to ATRA, differing only by one end functional group. As the chromophoric unit, is 
identical in each compound it is assumed that AT-retinol is equally susceptible to photo-
isomerisation as ATRA. 
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3.6 Proposed Explanation of Findings 
 
The lack of abnormal development following implantation of an AT-retinol 
containing bead was unexpected,  as Thaller and Eichele have demonstrated 
that retinol is converted to ATRA under physiological conditions.47,49  AT-retinol is 
also a known potent teratogen61. However,  our results suggest that retinol is a 
precursor, and is not biologically active itself.  They also suggest that a key 
regulatory step is the control of the rate of conversion of retinol to ATRA.  Thaller 
and Eichele state that the concentrations of endogenous retinol, retinal and 
ATRA in the limb bud were found to be about 600 nM,  15 nM and 25 nM 
respectively.49  The natural concentration of retinol in the limb is considerably 
higher, approximately 25 times, than that of ATRA.  This is consistent with a 
theory that retinol serves as a precursor for ATRA and is converted enzymatically 
as required.   
 
3.7 Conclusions 
 
The technique to test retinoids on chick limb buds has been optimised.  It was 
found that the shorter the time taken to perform the operation,  the greater the 
chance of survival.  With practice, operation times were reduced to below 
10 minutes.  One of the most common causes of embryos not surviving to 
examination is a poor seal.  It is essential to ensure the Sellotape™ is firmly 
stuck down to make a complete seal around the opening.  
 
Digit duplications from EC23 have successfully been reproduced but normal 
development was seen when AT-retinol was applied to the anterior margin of the 
limb bud.  An explanation for the lack of phenotype seen has been postulated;  
however,  further investigation is necessary before firm conclusions can be 
drawn about the effect of AT-retinol on the limb bud. 
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3.8 Future Work 
 
Further Investigation into Delivery of AT-Retinol to the Limb Bud  
 
It was initially thought that exogenous retinol applied to the limb bud  may be 
converted to ATRA and that digit duplications similar to those observed when 
ATRA is directly applied to the limb bud would occur.  However, despite 
numerous attempts, no digit duplication was seen on application of AT-retinol to 
the chick limb bud.  It was discussed previously in this report, that some kind of 
biological control may be effective,  preventing exogenous AT-retinol from being 
converted into teratogenic amounts of ATRA.  However,  before concluding that 
exogenous AT-retinol does not result in a teratogenic affect, it must first be 
ascertained that AT-retinol is actually being delivered to the limb bud.   
 
Eichele, Tickle and Alberts investigated the suitability of several different beads 
for the delivery of compounds such as ATRA, retinyl acetate and prostaglandin 
E1 to the chick limb bud.
62  Both in vitro loading / unloading assays and in vivo 
studies were carried out.  It was concluded that positively charged ion exchange 
resins, such as AG1-X2 and AG1-X8 were the most suitable for the controlled 
release of ATRA, and that uncharged acrylic ester polymer beads such as 
Amberlite XAD-7 and XAD-8 were better for controlled release of uncharged 
retinoids such as retinyl acetate.  Loading and unloading assays should be 
repeated using freshly derivatised AG1-X2 beads and also carried out using 
Amberlite XAD-7 and XAD-8 beadsxiii to determine the best bead for delivery of 
AT-retinol.  It should also be taken into account that AT-retinol isomerises readily 
in natural light and physiological conditionsxiv, which is a major reason for the 
                                                 
xiii XAD-7 and XAD-8 beads are the same size (150 – 200 µm diam) but have differing 
pore sizes.  AG1-X8 are slightly smaller (75 – 150 µm diam) 
xiv An NMR study on the stability of ATRA demonstrated that after only three days 
exposure to ordinary laboratory light, substantial isomerisation / degradation had 
occurred, such that approximately only 37% ATRA remained34. The structure of 
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development of more stable analogues such as EC23! Carrying out these assays 
in a dark room would reduce the likelihood of isomerisation occurring.  Once 
suitable beads have been found,  the in vivo experiments should be repeated 
using 0.1, 1.0 and 10.0 mg/ml concentrations of AT-retinol.  Again, carrying out 
these operations in a dark room would reduce the likelihood of isomerisation 
occurring. 
 
Alternative Technique for Assessing Teratogenicity and Toxicity 
Currently operations on chick limb buds, as described in this report, are carried 
out to test the affects of retinoids on the developing limb.  This method is 
advantageous in that it provides quantitative data about the teratogenicity and 
toxicity of the compounds tested.  However,  this delicate procedure is technically 
challenging and very time consuming.  Démarchez et al have reported an 
alternative method in which retinoid solutions are simply injected directly into the 
amniotic cavity of 10-day old chick embryos64.  At 16 days of incubation the eggs 
are then opened and observed as normal,  however in this case rather than 
looking for limb abnormalities,  the number of embryos presenting club-shapped 
feathers was recorded.  Log-probit analysis was then used to calculate the lethal 
embryotoxic dose (LED50d16) which provokes the death of 50% of the embryos at 
16 days of incubation and the effective dose (ED50) which induces production of 
club-shaped feathers in 50% of surviving embryos.   Démarchez et al found that 
the more active retinoids were also more toxic,  which is consistent with our 
previous findings.  In this alternative method, significantly less time is required for 
each operation, which is doubly advantages.  Firstly, more experiments can be 
carried out in a given time and secondly,  the length of time the embryo is 
exposed to the atmosphere is reduced,  thereby reducing the likelihood of 
infection.  Infection is a major cause of void results.  This alternative method 
could be used to quickly and quantitatively assess the teratogenicity and the 
                                                                                                                                                 
AT-retinol is closely related to ATRA, differing only by one end functional group. As the 
chromophoric unit, is identical in each compound it is assumed that AT-retinol is equally 
susceptible to photo-isomerisation as ATRA. 
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toxicity of new retinoid compounds synthesised. 
 
Further Investigation into the Metabolism of Synthetic Retinoids 
 
 
Scheme 2:  Left hand side: A schematic showing the metabolism of 
AT-retinol to ATRA, via AT-retinol. There is much evidence that this occurs.  
Right hand side:  It is currently believed that the body is unable to metabolise 
synthetic retinoids such as EC23 along the same route as its natural 
analogue. 
 
As discussed previously,  it is well documented that AT-retinol is metabolised to 
ATRA, via AT-retinal in the body.9  It was hypothesised that the metabolism of 
EC23 could be investigated by applying EC23-OH,  the EC23 analogue of 
AT-retinol,  to the limb bud by the methods described earlier and observing its 
effect on limb development.  EC23 is known to cause digit duplication, so 
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occurrence of digit duplication on application of EC23-OH may suggest that the 
chick limb bud is capable of metabolising EC23-OH to EC23,  see Scheme 2.  In 
order to carry out this study, EC23-OH should be made by hydrolysis of 7 
(EC23-OAc).  It would also be of interest to synthesis EC23-al (i.e. a synthetic 
analogue of AT-retinal) and also investigate this in the chick limb bud.  Again the 
occurrence of digit duplication would provide evidence of metabolism.  For 
completeness, the above investigations could be repeated using EC19 
analogues in the place of EC23 analogues.  
 
An alternative idea for further investigation into the metabolism of ATRA and 
EC23 has been inspired by a paper by on the role of ATRA in the morphogenesis 
of the neural tube.65  Maden et al have reported findings that quail embryos that 
have developed in the absence of ATRA undergo abnormal neural tube 
formation.  For example, neural tubes developed in these conditions had a wider 
floor plate,  a thicker roof plate and a different dorsoventral shape and as 
development continued,  the proliferation rate was found to decline drastically 
and neuronal differentiation was found to be highly deficient.    
 
We hypothesise that quail embryos developed in the absence of ATRA could be 
rescued by the timely application of exogenous ATRA.  Initial experiments would 
have to be conducted to determine the amount of ATRA required and the 
optimum stage at which to apply it order to prevent / reverse the abnormal 
development of neural tubes.  If successful,  then this could provide the bases for 
further investigation into the metabolism of synthetic retinoids.  The following 
hypothesises are made on the presumption that ATRA would successfully rescue 
quail embryos developed in the absence of ATRA.   
 
It is predicted that either AT-retinol or AT-retinal exogenously applied to embryos 
developed in the absence of ATRA would also induce rescue,  and that 
development would continue in the manner seen for those rescued directly by 
ATRA.  The reasoning for this is that AT-retinol and AT-retinal would be 
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metabolised to ATRA (see Scheme 2).  It is predicted that exogenous application 
of EC23,  a synthetic analogue of ATRA, would also rescue the quail embryos 
and again development would be expected to continue in a similar manner to 
those rescued directly by ATRA.  Although, it is likely that much lower 
concentrations would be required than needed for ATRA, in accordance to 
previous studies showing that EC23 is much more potent than ATRA.  Finally, it 
is predicted that exogenous application of either EC23-OH or EC23-al to quail 
embryos developed in the absence of ATRA would not rescue the quail embryos 
(see Scheme 2).  If the above predictions turn out to be correct, this would 
provide further evidence that EC23 behaves in a similar manner to ATRA,  but 
that the body is unable to metabolise EC23 or its derivatives.  Alternatively, if 
EC23-OH and/or EC23-al did induce rescue, this would be evidence that the 
body is able to metabolise synthetic retinoids. 
Synthesis of Luminescent Retinoids 
Currently much evidence of the role of ATRA within a developing organism has 
been obtained from gene reporter assays.  For example,  studies carried out on 
Raldh2 null mutant mice by Mic, Duester et al.66 have demonstrated the 
synthesis of / requirement for ATRA in several different areas of the organism 
during development.  However,  the limitation of these genetic studies is that they 
provide direct information only as to the whereabouts of particular genes / 
enzymes,  from which assumptions are then made as to the location of ATRA.  In 
general gene reporter assays will only reveal the places where a subset of 
retinoid targets can be activated and it is possible that gene reporter assays may 
under represent the retinoid activity in tissues.    
An alternative approach to learn more about the pathways of synthetic retinoids 
in vivo would be to synthesis retinoids that can be „tracked‟.  For example,  the 
synthesis of tritiated or 14C labelled retinoids,  or perhaps more simply, the 
synthesis of retinoids with extended polyene chains which are highly 
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luminescent.  Once in the system,  luminescent retinoids could then be observed,  
thus facilitating direct evidence for their distribution.  
 Chapter 4:   Experimental 
 
All air or moisture sensitive reactions were carried out under a dry nitrogen 
atmosphere using standard Schlenk techniques or in a glove box.  Glassware 
was oven dried before transfer into the glove box.  Hexane and THF were dried 
over sodium / benzophenone and acetonitrile was dried over CaH2 and all were 
distilled under nitrogen.  The solvents 1,4-dioxane, DMF, THF and DMSO were 
degassed by 3 freeze-pump-thaw-cycles.  Toluene was dried and deoxygenated 
by passage through columns of activated alumina and BASF-R311 catalyst 
under Ar pressure using a locally modified version of the Innovative Technology, 
Inc. SPS-400 solvent purification system. [Ir(μ-OMe)COD]2, was synthesised by 
literature procedures.  Hydrochloric acid was obtained from Fisher Scientific and 
all other compounds were obtained from Aldrich Chemical Company and tested 
for purity by GC-MS.  NMR spectra were recorded at ambient temperature on 
Bruker 400 Ultrashield (1H, 13C{1H},11B and 11B{1H}) Varian Unity 300 (11B and 
11B{1H}) and Bruker AC200 (13C{1H}) instruments. GC-MS analyses were 
performed on an Agilent 6890N gas chromatograph, equipped with a 5973 inert 
mass selective detector and a 10 m fused silica capillary column (DB-5ms). 
HRMS (ESI+) was performed on ThermoFinnagan 7.0T LTQ-FT.  HRMS (ASAP+) 
was performed on Waters Xevo QTOF. 
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6.1 Chemical Synthesis 
 
4,4,5,5,-Tetramethyl-2-[4-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-
2-ylethynyl)-phenyl]-[1,3,2]dioxaborolane  
 
 
 
6-(4-Bromo-phenylethynyl)-1,1,4,4-tetramethyl-1,2,3,4-tetrahydro-naphthalene (0.44 g, 
1.17 mmol), B2(pin)2 (0.30 g, 1.17 mmol) and K3PO42H2O (0.58 g, 2.34 mmol) were 
suspended in dioxane (3 ml).  A solution of Pd(OAc)2 (0.005 g, 0.023 mmol) and S-phos 
(0.024 g, 0.059 mmol) in dioxane (1 ml) was added and the reaction mixture was heated 
at 80 °C for 2 days whilst stirring.  The reaction was followed by GC-MS analysis.  After 
addition of water (100 ml) the product was extracted with diethyl ether (100 ml) and the 
organic fractions were washed with water (2 x 100 ml) then dried over MgSO4.  The 
ether solution was concentrated in vacuo.  The mixture was filtered through a silica plug 
with 20% dichloromethane/hexane and the solvent was removed in vacuo to yield an 
orange/yellow oil (0.08 g, 0.23 mmol, 20%). 1H NMR (400 MHz, CDCl3) δH: 7.77 (d, JH-H
 
= 7 Hz, 2H, Ar,), 7.51 (d, JH-H = 7 Hz, 2H, Ar), 7.47 (s, 1H, Ar), 7.27 (s, 2H, Ar) [No ortho 
splitting observed], 1.69 (s, 4H, CH2), 1.35-1.24 (m, 24H, CH3).  
13C{1H} NMR (125MHz, 
CDCl3) δ:  145.79, 145.2 (Ar), 134.70 (Ar), 130.88 (Ar), 130.14 (Ar), 128.86, 126.81 (Ar), 
120.17 (Ar), 111.46 (Ar), 91.47 (Ar-C≡C), 88.58 (C≡C-Ar), 84.07 (OC(CH3)2, pin), 35.10, 
32.03 (CH2), 34.49, 34.36 (Ar), 31.91, 31.84 (CH3), 25.03, 25.00 (CH3).  The carbon 
alpha to boron was not observed due to fast relaxation induced by the boron nucleus.  
MS (EI) m/z: 414 (M+), 399 (M-CH3). 
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4,4,5,5-tetramethyl-2-(5,6,7,8-tetrahydronaphthalene-2-yl)-1,3,2-
dioxaborolane   
 
 
 
[Ir(OMe)(COD)]2 (26 mg, 0.04 mmol), dtbpy (21 mg, 0.08 mmol) and B2pin2 (50 
mg, 0.20 mmol) were mixed in hexane (3 ml).  The pre-catalyst solution was 
added to a stirred solution of tetrahydronaphthalene (528 mg, 4 mmol) and B2pin2 
(950 mg, 3.74 mmol) in hexane (5 ml).  The reaction mixture was stirred at 80 °C 
for 18 hours.  The progress of the reaction was followed by GC-MS.  The 
reaction mixture  was diluted with dichloromethane/hexane (20/80 v/v) and 
passed through a short silica plug (5 cm) eluting with dichloromethane/hexane 
(20/80 v/v).  Removal of solvent in vacuo gave a colourless, transparent oil.  The 
product was crystallised  from methanol at -20 °C  as colourless needles (0.96 g, 
93% yield).   Mp 62.5 °C.  
11
B NMR (128 MHz, CDCl3) δ 31.05 (Bpin),  
1
H NMR 
(400 MHz, CDCl3): δ 7.52 (d, 2H, Ar, JH-H = 7 Hz), 7.08 (d, 1H, Ar, JH-H 7 Hz), 
2.78 (m, 4H, CH2),  1.79 (m, 4H, CH2), 1.34 (s, 12H, CH3).  
13C{1H} NMR (100 
Hz, CDCl3): δ 140.78 (Ar), 136.52 (Ar), 135.71 (Ar), 131.74 (Ar), 128.64 (Ar) 
83.59 (CMe2), 29.70 (Cy), 29.20 (Cy), 24.86 (Me), 23.27 (Cy), 23.13 (Cy), [C-B 
not observed due to quadrapolar broadening]. Analysis Calcd for C16H23BO2: C, 
73.79, H, 8.67 Measured – C-74.40, H-9.08; HRMS (ASAP+) Calcd for 
C16H23BO2: 257.1827, found 257.1793   
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Acetic acid 4-bromo-benzyl ester 
 
 
4-bromobenzyl bromide (2.5 g, 10.00 mmol) and potassium acetate (1.47 g, 
15.00 mmol) were added to a 500 ml round bottomed flask equipped with stirring 
bar.  Acetonitrile (150 ml)  was added.  A condenser was fitted and the reaction 
mixture was heated at 70 °C for 5 days.  GC-MS analysis showed the reaction 
had gone to completion.  The reaction mixture was filtered through a Celite pad 
then partitioned between diethylether and H2O. The organic layer was washed 
with H2O (150 ml),  dried (MgSO4) and the solvent removed in vacuo, to give a 
yellow oil (2 g,  8.73 mmol,  87% yield).  This was purified via column 
chromatography and crystallisation. mp 33.3 – 34.1°C  IR (nujol mull, KBr disc, 
cm-1)  1750 (C=O), 1598 (C-O)   1H NMR (400 MHz, CDCl3) δH:  7.49 (d, 2H, Ar, 
JH-H = 7 Hz)  7.24 (d, 2H, Ar, JH-H = 7 Hz),  5.06 (s, 2H, CH2),  2.11 (s, 3H, CH3);  
13C{1H} NMR (100 Hz, CDCl3): δ 170.86 (C=O) 135.21 (Ar) 131.90 (Ar, CH) 
130.11 (Ar, CH),  122.46 (Ar),  65.65 (CH3),  21.13 (CH2);  Analysis Calcd for 
C9H9O2Br: C, 47.19, H, 3.96 Measured – C-47.21, H-3.97; MS (EI) m/z 228 [M
+] 
 
Br
O
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6-Ethynyl-1,1,4,4-tetramethyl-1,2,3,4-Tetrahydronaphthalene  
 
 
6-iodo-1,1,4,4-tetramethyl-1,2,3,4-tetrahydronaphthalene (10 g, 31.8 mmol), 
copper iodide (60 mg, 0.32 mmol) and Pd(PPh3)2Cl2 (0.224 g, 0.32 mmol) were 
added to a 500 ml round bottomed flask under N2.  Dry toluene (150 ml) and dry 
triethylamine (75 ml) were added via cannula and trimethylsilyl acetylene (3.28 g, 
33.4 mmol, 4.7 ml) was added via a syringe. The reaction was stirred for 18 
hours at room temperature and changed from yellow to brown / black.  The 
volatiles were removed in vacuo and the residue was dissolved in a mixture of 
sodium carbonate, methanol and water.  Excess solvent was removed in vacuo 
and the product was extracted into dichloromethane and dried over magnesium 
sulphate and filtered.  The volume of solvent was reduced on a rotary evaporator,  
then evaporation at ambient temperature for 48 hours yielded the product as an 
orange / brown crystalline solid (4.84 g, 22.8 mmol, 72%); 1H NMR (400 MHz, 
CDCl3) δH: 7.47 (1H, s, Ar), 7.26 (2H, m, Ar, + CHCl3), 3.02 (1H, s, H-C≡C), 1.71 
(4H, s, CH2), 1.29 (12H, d, CH3, JHH=3 Hz) 
 
 
4
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Methyl 5',6',7',8'-tetrahydro-2,2'-binaphthyl-6-carboxylate 
 
 
6-pinacolboryl-1,2,3,4-tetrahydronaphthalene (0.24 g, 0.93 mmol), methyl 6-
bromo-2-naphthoate (0.234 g, 0.89 mmol), [PdCl2(dppf)] (15 mg, 0.0186 mmol) 
and K3PO42H2O (0.46 g, 1.86 mmol) were suspended in  
ipropanol / H2O (5:1; 6 
ml) and stirred at 80 °C for 5 days to give an orange/brown solution containing a 
grey precipitate.  The volatiles were removed under reduced pressure, the brown 
residue was redissolved in DCM/NaCl (aq.) and the organic layer was separated.  
After removal of the volatiles in vacuo the crude product was obtained as a 
yellow solid (0.14 g, 0.44 mmol, 50 %).   Flash chromatography 
[dichloromethane/hexane (25/75 v/v)] increased the purity and yielded a white 
solid; however, traces of an homocoupled product can still be seen in NMR and 
GC-MS spectra.  Melting range 131.0 – 131.9 °C.  IR (nujol mull, KBr disc, cm-1)  
1717 (C=O),  1H NMR (400 MHz, CDCl3) δH: 8.59 (s, 1H, Ar), 8.05 (dd, J = 9 Hz, 
2 Hz 1H, Ar), 8.02 (br s, 1H, Ar),   7.98 (d, J = 9 Hz, 1H, Ar),  7.90 (d, J = 9 Hz, 
1H, Ar),  7.78 (dd, J = 9 Hz, 2 Hz, 2H, Ar),  7.44 (m, 2H, Ar),  7.18 (d, J = 8 Hz, 
1H, Ar)  3.79 (s, 3H, CH3)  2.84 (m, 4H, CH2), 1.84 (m, 4H, CH2).  Other small 
peaks also present. 13C{1H} NMR (100 Hz, CDCl3): δ 167.52 (C=O), 141.54, 
138.17, 138.16, 137.53, 136.30, 131.91, 131.22, 130.19, 130.13, 128.52, 127.56, 
126.85, 126.01, 125.56, 124.97 (Ar), 51.67 (Me), 29.56, 29.17, 23.19, 21.97 
(alkyl), Other small peaks also present.  Analysis Calcd for C22H20O2: C, 83.51, 
H, 6.37 Measured – C-82.80, H-6.23; MS MS (EI) m/z 316 [M+]  
O
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4-((5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)ethynyl)benzyl 
acetate 
 
 
 
6-ethynyl-1,1,4,4,-tetramethyl-2,2,3,3,-tetrahydro-naphthalene (0.97 g, 4.59 
mmol), Pd(PPh3)2Cl2 (30 mg, 0.043 mmol) and CuI (8 mg, 0.041 mmol)  were 
placed in a Schlenk tube.  Acetic acid 4-bromo-benzyl ester (1.00 g, 4.37 mmol) 
was added, followed by triethylamine (100 ml) via cannula.  The reaction was 
stirred at 80 °C for 6 days.    GC-MS analysis showed complete consumption of 
starting materials. The solvent was removed in vacuo to give a tan coloured 
solid.   This was purified using flash chromatography, eluting with DCM/hexane 
(1:10).  The product was crystallised from DCM at 21 °C (0.1 g, 0.03 mmol, 1 % 
yield).   Mp 140 °C.  X-ray analysis confirms the product to be 4-((5,5,8,8-
tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)ethynyl) benzyl acetate. IR (nujol 
mull, KBr disc, cm-1)  1733 (C=O), [No signal observed for CC, attributed to lack 
of dipole moment in the molecule] 1H NMR (400 MHz, CDCl3) δH: 7.50 (dm, J = 
8 Hz, 2H, Ar) 7.45 (t, J = 2 Hz, 1H, Ar),  7.37 (dm, J = 8 Hz, 2H, Ar),  7.26 (d, J = 
2 Hz, 2H, Ar) 5.09 (s, 2H, CH2),  2.10 (s, 3H, CH3),  1.67 (s, 4H, CH2), 1.27 (d, J 
= 8 Hz 12H, CH3),  
13C{1H} NMR (100 Hz, CDCl3): δ170.79 (C=O),  145.66,  
145.09,  135.72,  131.72,  129.93,  128.72,  128.09,  126.67,  123.59,  120.04 
(Ar),  90.44,  87.87 (CC),  65.89 (Me), 34.99, 34.92, 34.35, 34.23 (Cy)  31.78, 
31.70 (Me) 20.98 (CH2)  Anal. Calcd. for C16H28O: C, 83.29, H, 7.83 Measured – 
C, 83.05, H, 7.81, MS (EI) m/z 360 [M+], 345 [M-CH3]. 
O
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3-((5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)ethynyl)benzyl 
acetate  
 
 
6-Ethynyl-1,1,4,4,-tetramethyl-2,2,3,3,-tetrahydronaphthalene (0.806 g, 3.80 
mmol), Pd(PPh3)2Cl2 (36 mg, 0.05 mmol) and CuI (36 mg, 0.19 mmol)  were 
transferred to a 150 ml round bottom flask with tap, equipped with stirrer bar.  
Triethylamine (60 ml) was added via cannula followed by acetic acid-3-iodo-
benzyl ester (1.00 g, 3.62 mmol), giving a dark yellow / orange solution.  The 
reaction was stirred at room temperature for 3 d.  The volatiles were removed in 
vacuo.  The crude product was filtered through a silica plug with Et2O as the 
elutant (orange / yellow solution). The solvent was removed in vacuo to give an 
orange / brown solid; this was dissolved in hexane/Et2O (1:5; 15 ml) and filtered 
through a silica plug with hexane (250 ml) then hexane/Et2O (1:5; 300 ml).  The 
solvent was removed in vacuo to give a pale orange / brown solid (3.84 g, 
1.07 mmol, 30 % yield).  Mp   72.4 – 72.8°C,  IR (nujol mull, KBr disc, cm-1)  2332 
(CC), 1742 (C=O), 1H NMR (400 MHz, CDCl3) δ 7.52 (s, 1H, Ar),  7.47 (m, 2H, 
Ar),  7.32 (m, 1H, Ar),  7.27 (m, 3H, Ar),  5.08 (s, 2H, CH2),  2.15 (s, 4H, Cy), 2.10 
(s, 3H, CH3),  1.27 (d, J = 7 Hz, 12H, CH3).   
13C{1H} NMR (100 Hz, CDCl3): δ 
170.89 (C=O),  145.77,  145.19,  136.28,  131.44,  131.35,  130.05,  128.80,  
128.64,  127.87,  126.78,  124.09,  120.10 (Ar),  90.47,  87.92 (CC),  
65.90 (Me), 35.09,  35.02,  34.45,  34.33 (Cy),  31.88,  31.80 (Me),  21.08 (CH2).  
Analysis Calcd for C25H28O2: C, 83.29, H, 7.83, Measured – C, 80.79, H, 8.12; 
MS MS (EI) m/z 360 [M+], 345 [M-CH3] HS-MS submitted 24/6/10 HRMS 
(ASAP
+
) Calcd for C25H28O2: 361.21621, found 361.21623 
O
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6.2  Biological Procedures 
Storage and Pre-treatment of Eggs 
Eggs were refrigerated until needed.  Before incubation, the egg shell was 
cleaned with 70% ethanol.  A small hole (~2 mm diameter) was made through 
the shell and a small amount of albumen removed with a syringe.  The eggs were 
them incubated at 37 °C for 4 days.  Increasing or decreasing the incubation 
temperature respectively speeds up or slows down development.  The optimum 
stage for the operations discussed here is Hamburger and Hamilton stage 20,60 
reached after approximately 4 days of incubation at  37 °C. 
Formate Derivatisation of AG1-X2 Beads 
(Method adapted from ”AG1, AG MP-1 and AG 2 Strong Anion Exchange Resin 
Instruction Manual” BIO-RAD p. 10-11) 
1 M Formic Acid 
1.15 g of formic acid (powder) was added to a 50 ml centrifuge tube and the 
solution volume was made up to 25 ml with deionised water. 
 
1 M NaOH 
1 g of NaOH (solid) was added to a 50 ml centrifuge tube and the solution 
volume was made up to 25 ml with deionised water. 
1 g AG1-X2 beads were added to a 50 ml centrifuge tube.  NaOH (aq) (10 ml x 
1 M) was added and left agitating for 1 h.  The suspension was left to settle then 
the excess NaOH (aq) was removed with a plastic pipette.  The remaining NaOH 
solution (15 ml) was added and returned to the agitator for 1 h.   The excess 
NaOH (aq) was removed and the beads were rinsed with phosphate buffered 
saline (2 x 30 ml) and then with deionised water (4 x 30 ml). Deionised water 
(25 ml) was added to the beads which were agitated (30 min).  The excess water 
was removed and the beads were given a final rinse with deionised water 
(25 ml).  Formic acid solution (12 ml x 1 M) was added and the beads were left 
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agitating for 1 h.   The suspension was left to settle and then the excess formic 
acid (aq) was removed with a plastic pipette.  The remaining formic acid (13 ml) 
was added and the tube was returned to the agitator for 1 h.   The excess formic 
acid (aq) was removed.  The beads were dried on filter paper for 48 h and then 
were transferred to a screw topped centrifuge tube until required. 
 
Biological Saline   (Made up Daily) 
5 ml Tyrode‟s solution (contains: NaCl, KCl, CaCl26H2O, NaHCO3,  NaH2PO4, 
glucose and distilled water) 
0.050 g glucose 
0.050 g NaHCO3 
0.5 ml  antibiotic / antimitotic 
50 ml reverse osmosis purified water 
 
Implantation of Bead 
The surface of the egg was wiped with 70 % ethanol to clean it.  Forceps were 
used to remove a small area of shell, whilst keeping the inner membrane intact to 
protect the embryo from falling shell.  The membrane was then peeled back to 
access the embryo.  2-4 drops of biological saline were added to protect the 
embryo and improve clarity.  Whilst viewing under a microscope, a tungsten 
needle is used to gently peel back the outer vitelline membrane to the reveal 
area surrounding the limb bud (approx 1.5cm3).  The membranes close to the 
limb bud also had to be cleared using a tungsten needle.  Once the limb-bud was 
exposed, the needle was used to cut a „flap‟, slightly longer than the diameter of 
the bead, along the anterior margin.  Fine forceps were used to remove a bead 
(AG1-X2, formate derivatised) from the retinoid solution (e.g. 0.1 mg/ml 
AT-retinol in biological grade DMSO); this was dipped briefly (3 sec) in biological 
saline and then inserted under the „flap‟.  The bead was released from the 
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forceps by squeezing, then releasing.  Sellotape Original™ was used to create 
air tight seal over the window and the embryo was incubated at 37 °C for 7 days.  
After this time, scissors were used to reopen the window and observe the 
embryo. 
 
Dilution Series (Carried out in duplicate) 
A set of small Eppendorf tubes were labelled from A to G. 10 µl of DMSO was 
pipetted into tubes B-G.  20 µl x 0.1 mg/ml of EC23 in DMSO was added to tube 
A, which was then centrifuged (12 sec) and vortexed (5 sec).  10 µl of the EC23 
solution from tube A was transferred to tube B using a Gilson pipette.  Tube B 
was then centrifuged (12 sec), and vortexed (5 sec), and 10 µl of the solution 
was transferred to tube C.  This process was continued until each tube contained 
a solution of EC23.  The absorbance of each sample at λ = 306 nm was 
measured using a NanoDrop spectrophotometer ND-1000. 
 
The above process was repeated using a stating solution of 0.1 mg/ml EC23 in 
DMSO. 
 
Loading Assay (Carried out in triplicate) 
40 x AG1-X2 beads were soaked in A.C.S. spectrophotometric grade DMSO 
(200 µl) in a small Eppendorf tube for 2 h.  The Eppendorf tube was vortexed, 
then centrifuged, then DMSO (180 µl) was replaced with AT-retinol in DMSO 
solution (180  µl x 0.1 mg/ml).  Samples were immediately vortexed and 
centrifuged and a 5 µl aliquot was immediately taken.  Further 5 µl aliquots were 
taken at given times, vortexing and centrifuging before each.  The samples were 
frozen for 7 days before being analysed on a NanoDrop spectrophotometer.  
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Unloading Assay (Carried out in triplicate) 
The beads from the loading assay (above) were left soaking in the AT-retinol in 
DMSO solution for 24 h.  The excess retinol solution was then removed and 
replaced with saline (200 µl).  The samples were immediately vortexed and 
centrifuged and a 5 µl aliquot was immediately taken.  Further 5 µl aliquots were 
taken at given times, vortexing and centrifuging before each one.  The samples 
were analysed on a NanoDrop spectrophotometer. 
 
Control Assay (Carried out in duplicate) 
40 x AG1-X2 beads were put in a small Eppendorf tube and centrifuged (30 sec).  
A.C.S. DMSO (200 µl) was added and the tube was vortexed (10 sec) and 
centrifuged (30 sec).  A 5 µl sample was taken immediately. The beads were left 
to soak for 24 h, then 180 µl of DMSO was removed and replaced by fresh 
DMSO.  The sample was  vortexed (10 sec), centrifuged (30 sec) and a 5 µl 
sample was taken immediately. A final 5 µl sample was taken after 5 min.  The 
absorbance of all samples at λ = 284 nm was measured and found to be zero. 
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